Replies to post #169536 on Biotech Values

[bladerunner1717]

Pipper Jaffray upgrades GERN



“The efficacy data appears compelling and is certainly sufficient for progression into a Geron-sponsored Phase 2 study,” Charles Duncan, an analyst with Piper Jaffray & Co., wrote today in a research note. He raised his price target for the shares to $10 from $6.


Bladerunner

[poorgradstudent]

GERN:

I find it somewhat humorous that people doesn't trust Tefferi when he says that they got CRs. The man, together with all other KOL in MF recently redefined the criteria.

You should really read the paper at the link.

And the Jakafi data are easy to find.